Only Sjögren's syndrome Phase 2 trial to meet the primary endpoint in both patient population types Patients with moderate-to-severe systemic disease activity (ESSDAI score =5) treated
Only Sjögren’s syndrome Phase 2 trial to meet the primary endpoint in both patient population types Patients with moderate-to-severe systemic disease activity treated with. | May 31, 2023
First-Quarter 2023 Results: Net Sales of $832.1 Million GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million TEPEZZA® Net Sales of $405.3 Million . | May 3, 2023
Fourth-Quarter 2022 Results: Net Sales of $942.0 Million GAAP Net Income of $120.4 Million; Adjusted EBITDA of $357.5 Million; Includes $37.3 Million of Acquired IPR&D and Milestones Expenses
Trial also met primary endpoint in first study population as announced September 2022 - The Company plans to work with the FDA to design a Phase 3 program to begin in 2023, ahead of expectations - Horizon